Lallemand Health Solutions has announced it will be showcasing its portfolio of clinically documented microbiome solutions at this year's Vitafoods Bangkok, taking place September 2-4.
The probiotic and yeast specialist will demonstrate how it can support brands looking to capitalise on fast-growing health opportunities across the Asia-Pacific (APAC) region.
As consumers across APAC increasingly seek proactive approaches to ageing well, maintaining cognitive performance, supporting digestive health and improving overall wellbeing, Lallemand has continued to invest in science-backed biotic innovations designed to deliver meaningful health benefits and strong market differentiation.
"Asia-Pacific remains one of the most dynamic and innovative health ingredients markets in the world," said Romane Maillet, Product Category Manager.
At Vitafoods Bangkok, we look forward to sharing new clinical findings and helping our partners develop next-generation microbiome solutions that respond to evolving consumer expectations.
Healthy ageing: supporting mobility, vitality and quality of life
Healthy ageing is increasingly important in the APAC region due to a growing ageing population and consumer interest in maintaining vitality.
At Vitafoods Bangkok, Lallemand will present Cerenity, a clinically validated probiotic that promotes healthy ageing through the gut-muscle axis. Recent research also shows its positive effects on physical performance and quality of life in older adults.
The company's healthy ageing platform additionally includes solutions for cardiovascular and cognitive health, enabling brands to create comprehensive wellness offerings for older consumers.
New insights into cognitive performance
Demand for solutions supporting focus, mental performance and cognitive resilience has continued to grow across APAC, particularly among students, professionals, gamers and active older adults.
Lallemand said that it will present new data supporting its expanding cognitive health portfolio, including results from a recent clinical study evaluating Cerebiome in action video gamers.
Preliminary findings demonstrated measurable improvements in several attention-related parameters, including reaction time and processing speed.
These results further reinforce the growing evidence supporting the gut-brain axis and open new opportunities for brands targeting cognitive capacities and mental performance.
Clinically documented solutions for women's health
Lallemand said that it will also present its portfolio of targeted probiotic solutions supporting women's health across key life stages, featuring innovations such as:
- Prenatis, evaluated in a clinical study involving 180 pregnant women, demonstrating benefits for maternal health and early infant microbiome development
- Lacidofil, shown to support microbiota balance around C-section delivery
- L. plantarum Rosella, supported by six clinical studies involving more than 800 women, for vaginal microbiota balance
- B. bifidum Rosell-71, clinically evaluated for digestive comfort during menstruation.
Together, these solutions provide healthcare-focused brands with scientifically substantiated approaches to female health and wellbeing through microbiome modulation.
Visitors to booth #H7-P41 will have the opportunity to meet Lallemand Health Solutions experts, explore recent clinical developments, discuss product innovation opportunities and discover FizzBiotics by Lallemand, an engaging sparkling probiotic concept designed to elevate consumer experience and support product differentiation.
Brands can utilise Lallemand Health Solutions' comprehensive expertise in scientific research, regulatory compliance and manufacturing to drive innovation in products for healthy ageing, cognitive health, digestive wellness and women's health.
